<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230853</url>
  </required_header>
  <id_info>
    <org_study_id>BAN2401-A001-101</org_study_id>
    <nct_id>NCT01230853</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate the safety and tolerability of BAN2401 at
      sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multicenter, double-blind, randomized, placebo-controlled study in subjects
      with mild to moderate Alzheimer's disease. The study will comprise separate single dose
      ascending (SAD) and multiple dose ascending (MAD) parts designed to allow the MAD part to be
      initiated while the SAD part is ongoing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Ascending Dose (SAD)</measure>
    <time_frame>baseline to Day 180 post-dose</time_frame>
    <description>To evaluate the safety and tolerability of single intravenous (i.v.) infusions of BAN2401 at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Ascending Dose(MAD)</measure>
    <time_frame>baseline to Day 264 post-dose</time_frame>
    <description>To evaluate the safety and tolerability of 4 monthly i.v. infusions of BAN2401 at sequentially ascending doses in subjects with AD</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Active Comparator: A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: A</intervention_name>
    <description>BAN2401 Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)</description>
    <arm_group_label>Active Comparator: A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator B</intervention_name>
    <description>Placebo Matching Placebo Infusion</description>
    <arm_group_label>Placebo Comparator B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator B</intervention_name>
    <description>BAN2401 Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)</description>
    <arm_group_label>Active Comparator: B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator A</intervention_name>
    <description>Placebo Matching Placebo Infusion</description>
    <arm_group_label>Placebo Comparator A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Clinical diagnosis of probable mild to moderate Alzheimer's disease (AD) by National
             Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's
             Disease and Related Disorders Association Alzheimer's (NINCDS-ADRDA) criteria.

          2. A Mini Mental State Examination (MMSE) score of 16 to 28, inclusive, at Screening.
             Subjects recruited to the first 2 SAD cohorts should have an MMSE of &gt; 22.

          3. Where symptomatic treatment of Alzheimer's disease (AD) is clinically indicated,
             subjects must be on stable treatment (e.g., with an anticholinesterase inhibitor
             [AChEI] and/or memantine) for at least 12 weeks prior to the Screening visit.

          4. On stable doses of all other prescribed medications for at least 4 weeks prior to the
             screening visit.

        Exclusion:

          1. Any neurological condition that could be contributing to cognitive impairment above
             and beyond that caused by the subject's Alzheimer's disease (AD).

          2. Any psychiatric diagnosis or symptoms, e.g hallucinations, major depression, or
             delusions, that could interfere with assessment of cognition in the subject.

          3. History of transient ischemic attack (TIA), stroke, or seizures within 12 months of
             Screening.

          4. Evidence of infection, tumor, stroke or other clinically significant lesions that
             could indicate a dementia diagnosis other than AD on brain magnetic resonance imaging
             (MRI) at Screening.

          5. Other significant pathological findings on brain MRI at Screening, including but not
             limited to: more than 3 micro-hemorrhages, single macro-hemorrhage; evidence of
             vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular
             malformations or space occupying lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eisai Medical Services</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City, UT</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

